Anisms of killing by antiCD20 monoclonal antibodies. Mol Immunol 2007, 44:3823837. Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, Introna M: Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis by way of CD16B additional efficiently than rituximab. Blood 2013, 122:3482491. Mossner E, Brunker P, Moser S, Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jager C, Strein P, Fertig G, Friess T, Schull C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umana P: Growing the efficacy of CD20 antibody therapy by way of the engineering of a new form II anti-CD20 antibody with enhanced direct and immune effector cellmediated B-cell cytotoxicity. Blood 2010, 115:4393402. Cartron G, Watier H, Golay J, Solal-Celigny P: From the bench towards the bedside: approaches to strengthen rituximab efficacy. Blood 2004, 104:2635642. Wang SY, Racila E, Taylor RP, Weiner GJ: NK-cell activation and antibodydependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 2008, 111:1456463. Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, Wijayaweera SS, Dixon SV, Kim H, Cox KL, Kerr JP, Johnston DA, Johnson PW, Verbeek JS, Glennie MJ, Cragg MS: Antigenic modulation limits the efficacy of antiCD20 antibodies: implications for antibody selection. Blood 2010, 115:5191201. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M: Obinutuzumab plus chlorambucil in individuals with CLL and coexisting situations. N Engl J Med 2014, 370:1101110. Radford J, Davies A, Cartron G, Morschhauser F, Salles G, Marcus R, Wenger M, Lei G, Wassner-Fritsch E, Vitolo U: Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results with the GAUDI study (BO21000). Blood 2013, 122:1137143. Morschhauser FA, Cartron G, Thieblemont C, Solal-Celigny P, Haioun C, Bouabdallah R, Feugier P, Bouabdallah K, Asikanius E, Lei G, Wenger M, Wassner-Fritsch E, Salles GA: Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse significant b-cell lymphoma or mantle-cell24.Aflatoxin M1 25.Lanosterol 26.PMID:24238102 27.28.29.30.31.32.33.34.35.36.lymphoma: benefits in the phase II GAUGUIN study. J Clin Oncol 2013, 31:2912919. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, Parren PW, Glennie MJ, van de Winkel JG: The biological activity of human CD20 monoclonal antibodies is linked to one of a kind epitopes on CD20. J Immunol 2006, 177:36271. Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, Jarjoura D, Tridandapani S, Muthusamy N, Byrd JC: Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol 2013, 190:2702711. Wierda WG, Kipps TJ, Mayer J, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A: Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010, 28:1749755. Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A: Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab.